Role of Insulin-Like Growth Factor I in Maintaining Normal Glucose Homeostasis
|
|
- Della Booker
- 8 years ago
- Views:
Transcription
1 Efficacy HORMONE RESEARCH Horm Res 2004;62(suppl 1):77 82 DOI: / Role of Insulin-Like Growth Factor I in Maintaining Normal Glucose Homeostasis David R. Clemmons Department of Medicine, UNC School of Medicine, Chapel Hill, N.C., USA Key Words Adults W Diabetes mellitus W Gene polymorphisms W Glucose metabolism W Growth hormone W Insulin-like growth factor I W Insulin sensitivity Abstract Insulin-like growth factor I (IGF-I) has significant structural homology with insulin. IGF-I has been shown to bind to insulin receptors to stimulate glucose transport in fat and muscle, to inhibit hepatic glucose output and to lower blood glucose while simultaneously suppressing insulin secretion. However, the precise role of IGF-I in maintaining normal glucose homeostasis and insulin sensitivity is not well defined. Studies in patients with diabetes have shown that in insulin-deficient states, serum IGF-I concentrations are low and increase with insulin therapy. Similarly, administration of insulin via the portal vein results in optimization of plasma IGF-I concentrations. A patient with an IGF1 gene deletion was shown to have severe insulin resistance that improved with IGF-I therapy. Studies conducted in experimental animals have shown that if IGF-I synthesis by the liver is deleted, the animals become insulin-resistant, and this is improved when IGF-I is administered. Likewise, deletion of the IGF-I receptor in muscle in mice induces severe insulin resistance. Administration of IGF-I to patients with type 2 diabetes mellitus has been shown to result in an improvement in insulin sensitivity and a reduction in the requirement for exogenously administered insulin to maintain glucose homeostasis. A polymorphism in the IGF1 gene that has been shown to reduce serum IGF-I results in an increased prevalence of type 2 diabetes. Taken together, these findings support the conclusion that IGF-I is necessary for normal insulin sensitivity, and impairment of IGF-I synthesis results in a worsening state of insulin resistance. Introduction Copyright 2004 S. Karger AG, Basel Insulin-like growth factor I (IGF-I) circulates in relatively high concentrations in human serum. Concentrations of IGF-I in serum are dependent upon a balance of hormones, which include growth hormone (GH) secreted by the pituitary gland but also insulin, particularly as it pertains to its actions in the liver. Therefore, normal hepatic insulin action is required for normal rates of IGF-I synthesis [1]. ABC Fax karger@karger.ch S. Karger AG, Basel /04/ $21.00/0 Accessible online at: Dr. D.R. Clemmons CB 7170 Endocrinology UNC School of Medicine Chapel Hill, NC (USA) Tel , Fax , endo@med.unc.edu
2 Fig. 1. Increase in serum IGF-I concentrations following insulin administration. Insulin was given by conventional subcutaneous (S.C.) injections, intensive S.C. injections or portal vein infusion. The results show that portal vein administration results in a much greater increase in serum IGF-I. actions of IGF-I, whereas mature adipocytes and liver appear to be very insensitive to IGF-I and to rely almost solely on insulin receptors to mediate glucose-lowering effects. Therefore, in severely insulin-deficient states, administration of pharmacological amounts of IGF-I is not able to reverse the consequences of insulin deficiency, presumably because it fails to act on adipose tissue and liver. Conversely, in severe IGF-I-deficient states, insulin action in skeletal muscle appears to be impaired [5]. However, one complication in interpreting in vivo studies of IGF-I deficiency is that this condition is invariably accompanied by supraphysiological concentrations of GH. These high GH concentrations lead to anti-insulin effects in both liver and fat, which worsen insulin resistance [6]. Therefore, determining the precise role of IGF-I deficiency in altering insulin action is complicated by these compensatory changes. The recent ability to delete IGF-I synthesis in tissues selectively has shed new light on the mechanisms that mediate these effects. Insulin-Deficient States in Humans When insulin secretion and actions are normal and when normal rates of IGF-I synthesis are maintained, the IGF-I that is present in interstitial fluid binds to both IGF-I receptors and hybrid insulin/igf-i receptors, which are formed by combining one alpha and one beta subunit from the insulin receptor and one alpha and one beta subunit from the IGF-I receptor [2]. As the affinity of the insulin receptor homodimer for IGF-I is 200-fold lower than that for insulin, it is doubtful whether IGF-I exerts its actions through the insulin receptor homodimer. However, hybrid receptors have a 20-fold higher affinity for IGF-I compared with insulin, and they have been shown to activate insulin receptor-linked signalling mechanisms [3]. Therefore, this provides a mechanism whereby physiological concentrations of IGF-I may stimulate insulinlike actions. Regardless of the receptor subtype that is utilized, in most tissues IGF-I has been shown to stimulate insulinlike actions in vitro, including stimulation of glucose transport, glucose oxidation and translocation of the glucose transporter GLUT-4 to the plasma membrane [4]. The extent to which IGF-I, as opposed to insulin, participates in this process under basal conditions has been difficult to define. There appear to be major differences among tissues in the capacity of IGF-I to exert these actions. Skeletal muscle is an insulin target tissue that appears to be particularly sensitive to the insulin-like Severe insulin deficiency is accompanied by low serum IGF-I concentrations [7]. When patients with type 1 diabetes mellitus who had not received insulin therapy were assessed, their blood IGF-I concentrations were below the lower limit of normal. In response to insulin injections, IGF-I concentrations rose 2.5-fold in a 3-day period. Similarly, experimental studies in rats have shown that normal IGF-I synthesis by the liver requires normal portal vein insulin secretion [8]. This finding has been confirmed in humans. Patients with type 1 diabetes who received insulin by portal vein infusion for 6 months were compared with control volunteers who received intensive insulin therapy by peripheral injection, and plasma IGF-I concentrations were measured. IGF-I was at least 60% higher at steady state in the controls who received portal vein insulin (fig. 1) [9]. This suggests that optimum insulinization of the liver is necessary for optimal IGF-I plasma concentrations. Similarly, IGF-binding protein 1 (IGFBP-1), whose synthesis is suppressed by insulin and, importantly, controls the concentrations of free IGF-I that are available to bind to receptors, was optimally suppressed with portal vein insulin, whereas peripheral vein insulin resulted in suboptimal suppression. Thus, free IGF-I concentrations would be expected to be disproportionately increased in the patients who received portal vein insulin. This increase in IGF-I may be required for optimum insulin sensitization in the periphery. 78 Horm Res 2004;62(suppl 1):77 82 Clemmons
3 Studies of patients with rare genetic syndromes have also furthered our understanding of the necessity for normal IGF-I concentrations to maintain normal insulin sensitivity in humans. A single patient who had a severe IGF1 gene deletion has been described. This patient had serum IGF-I concentrations that were!2% of normal, and GH injections failed to stimulate growth. The patient had a 3.6-fold reduction in insulin sensitivity compared with normal age-matched controls. After 6 months of IGF-I therapy, this defect in insulin sensitivity was completely reversed, suggesting that maintenance of normalto-high serum IGF-I concentrations resulted in optimization of insulin action [10]. Similarly, long-term studies in patients with severe insulin resistance caused by mutations in the insulin receptor show that IGF-I is capable of lowering haemoglobin A1c by 1.8% over a 9-month treatment interval [11]. This strongly suggests that, in the absence of normal insulin action, IGF-I is able to augment insulin-like signalling, which leads to improvement of glucose metabolism. Tissue-Specific Gene Deletions in Mice The ability to selectively alter IGF-I synthesis in tissues has led to new insights into the role of IGF-I in maintaining insulin sensitivity and the role of blood transport of IGF-I compared with autocrine/paracrine-synthesized IGF-I, which occurs in peripheral tissues. Elimination of IGF-I synthesis specifically in hepatocytes leads to an 80% reduction in serum IGF-I in mice [12]. While these animals have a minimal growth retardation, for example only a 6% reduction in final adult length, they show significant abnormalities in carbohydrate metabolism. When an insulin tolerance test was performed, the animals that had low serum IGF-I concentrations had impaired glucose clearance compared with control animals, and the impaired glucose clearance was observed in spite of a 3.2- fold increase in plasma insulin concentrations. This suggested that the animals were significantly insulin-resistant and that this defect resulted from plasma IGF-I deficiency. This possibility was confirmed by administering IGF-I to these animals, which resulted in increased plasma IGF-I and restoration of the glucose response to an acute insulin injection to normal. This strongly suggests that maintenance of a normal plasma IGF-I concentration is required for normal insulin sensitivity. However, these studies are complicated by the observation that GH secretion is also elevated in these animals due to a lack of normal feedback suppression of GH synthesis. To analyse this model further, these investigators deleted hepatic synthesis of the acid-labile subunit (ALS), a component of the IGF-I/IGFBP-3/ALS complex. They also created animals in which there was reduced hepatic synthesis of both IGF-I and ALS. Plasma IGF-I was further reduced in these animals, and this resulted in a decrease in adult size of approximately 30%. These severely IGF-I-deficient animals had an increase in free IGF-I in their serum, probably because their amount of IGFBP-3 was disproportionately reduced because of rapid clearance caused by loss of the IGF-I/IGFBP-3/ALS complex. These animals had less impairment of glucose intolerance, probably due to maintenance of relatively high free IGF-I concentrations [13]. A further model that was studied was deletion of the IGF-I receptor in skeletal muscle. This was complicated by the observation that deletion of the IGF-I receptor in skeletal muscle also results in deletion of the hybrid insulin/igf-i receptor [5]. When both of these receptors were deleted, however, the animals developed glucose intolerance at age 8 weeks and overt diabetes at 3 months. These animals were significantly insulin-resistant. This finding suggests that, at least in skeletal muscle, some IGF-I- or hybrid receptor-related signalling is necessary to maintain normal glucose homeostasis. This is important because these animals did not have elevated plasma GH concentrations. Therefore, it appears in mice that both normal GH secretion and adequate IGF-I action in skeletal muscle are required for maintenance of normal glucose homeostasis. Other experimental models have reinforced these conclusions. Specifically, the creation of IGFBP-1 transgenic mice has been associated with abnormal glucose dynamics. These animals are important because they do not have elevated GH concentrations [14]. In this state, when serum IGFBP-1 concentrations are elevated because of transgenic forced overexpression, they develop impaired glucose tolerance and the blood glucose-lowering effect of an IGF-I injection is less than in control animals, suggesting that the binding protein is functioning to affect the ability of IGF-I to increase insulin sensitization. Furthermore, when intraperitoneal glucose tolerance tests were conducted, the sensitivity of these animals to an insulin injection was impaired, and this resulted in higher blood glucose concentrations with higher concomitant serum insulin levels. Finally, when the IGFBP-1 transgenic mice were studied at various ages, and simple glucose tolerance tests were performed, there was an age-dependent deterioration in glucose tolerance, with animals at 44 weeks showing a diabetic glucose tolerance test compared with the control animals at IGF-I in Glucose Homeostasis Horm Res 2004;62(suppl 1):
4 44 weeks. This suggests that maintenance of normal free IGF-I concentrations is required for maintenance of normal glucose homeostasis in aged animals. Human Studies Human studies are by definition more complex because of the inability to create selective tissue deficits in IGF-I secretion or action. However, administration of IGF-I for 6 weeks to patients with type 2 diabetes resulted in lowering of blood glucose concentrations throughout the day (fig. 2) and lowering of serum insulin levels. Formal insulin sensitivity testing showed a 3.4-fold improvement in insulin sensitivity that resulted in improvement in the insulin sensitivity index values to near normal (fig. 3) [15]. Confirmation of this finding was obtained in 228 adult volunteers who received IGF-I therapy for 12 weeks at four different dosages. The two highest dosages resulted in substantial lowering of fasting and mean daily blood glucose. Haemoglobin A1c was improved by 1.6% compared with control participants, who received no IGF-I [16]. This strongly suggested that IGF-I was improving insulin sensitivity, which resulted in improvements in glucose metabolism. The molecular mechanism by which IGF-I enhances insulin sensitivity in humans has been analysed, but not completely delineated. IGF-I is capable of binding to hybrid insulin/igf-i receptors in skeletal muscle. This binding to the hybrid receptor selectively stimulates phosphorylation of the insulin receptor beta subunit and activation of insulin receptor substrate 1, the principal downstream signalling molecule activated by insulin binding [3]. This results in enhancement of insulin-stimulated glucose transport in this tissue, an important insulin-like action. The effect can be blocked with an antibody that is specific for IGF-I binding to the IGF-I receptor, which suggests that the effect is truly mediated through the hybrid receptor. The human studies up to this point have analysed the effect of pharmacological doses of IGF-I, and therefore they do not shed much light on the role of normal IGF-I ± ± ± Fig. 2. Modal day glucose values in type 2 diabetes before and after IGF-I administration. IGF-I, 40 Ìg/kg, bid was given subcutaneously to 13 patients with type 2 diabetes. Glucose values were measured at the times shown before treatment and after 6 weeks of therapy. The arrows denote the times of meals. Reprinted with permission from Moses et al. [15], from the American Diabetes Association. Copyright 1996 American Diabetes Association. Fig. 3. Change in insulin sensitivity after IGF-I administration. Insulin sensitivity was measured following a frequently sampled intravenous glucose tolerance test. The changes in the mean values and those for each individual are shown. Reprinted with permission from Moses et al. [15], from the American Diabetes Association. Copyright 1996 American Diabetes Association. 80 Horm Res 2004;62(suppl 1):77 82 Clemmons
5 secretion and maintenance of normal insulin action. Recent epidemiological studies have suggested, however, that maintenance of normal serum IGF-I may be required for maintenance of normal insulin sensitivity. Studies from The Netherlands have shown that 12% of Caucasians have a polymorphism in the promoter region of the IGF1 gene [17]. This results in a reduction in serum IGF-I of approximately 40% in affected individuals. More importantly, these individuals had a prevalence of type 2 diabetes increased by 1.7-fold and prevalence of myocardial infarction increased by 3.4-fold, compared with agematched controls 160 years of age, who do not have the polymorphism. These individuals are also approximately 2.1 cm shorter than controls [18]. The findings suggest that this polymorphism results in some attenuation of final adult height and increased insulin resistance, which leads to a higher rate of development of type 2 diabetes and vascular disease. The findings further suggest that maintenance of normal serum levels of IGF-I is required for long-term maintenance of normal insulin sensitivity, and IGF-I deficiency leads to an increased prevalence of insulin resistance and the development of type 2 diabetes. impaired are associated with lower serum IGF-I concentrations. Conversely, lowering of serum IGF-I concentration increases insulin resistance and restoration of serum IGF-I to normal ameliorates insulin resistance both in experimental animals and humans. In these states, however, it has not been possible to completely delineate the mechanism of action by which IGF-I improves insulin sensitivity. The ability of IGF-I to enhance insulin sensitivity in liver and adipocytes is indirect, and its major effect appears to be mediated through lowering serum GH concentrations, which reduces the anti-insulin actions of GH that are mediated in these tissues. In skeletal muscle, however, reduction of insulin sensitivity may also be due in part to loss of direct effects of IGF-I. Specifically, IGF-I binds to hybrid insulin/igf-i receptors in skeletal muscle, which may result in enhanced insulin-like signalling in this tissue. It is also possible that other peripheral tissues require IGF-I action to maintain normal insulin sensitivity. Future studies will be required to further determine the role of IGF-I in maintaining normal sensitivity to insulin and in reducing the effects of supraphysiological concentrations of GH on deterioration of glucose metabolism. Conclusion IGF-I is an important signalling molecule for maintenance of normal insulin sensitivity. States in which insulin secretion is reduced or insulin action is markedly Acknowledgements The author wishes to thank Ms. Laura Lindsey for her help in the preparation of the manuscript. This work was supported by a grant from the National Institutes of Health HL References 1 Boni-Schnetzler M, Schmid C, Meier PJ, Froesch ER: Insulin regulates insulin-like growth factor I mrna in rat hepatocytes. Am J Physiol 1991;260:E846 E Seely BL, Reichart DR, Takata Y, Yip C, Olefsky JM: A functional assessment of insulin/insulin-like growth factor-i hybrid receptors. Endocrinology 1995;136: Sakai K, Lowman HB, Clemmons DR: Increases in free, unbound insulin-like growth factor I enhance insulin responsiveness in human hepatoma G2 cells in culture. J Biol Chem 2002;277: Dimitridas G, Parry-Billings M, Bevan S, Dunger D, Piva T, Krause U, Wegener G, Newsholme EA: Effects of insulin-like growth factor- I on the rates of glucose transport and utilization in rat skeletal muscle in vitro. Biochem J 1992;285: Fernandez AM, Kim JK, Yakar S, Dupont J, Hernandez-Sanchez C, Castle AL, Filmore J, Shulman GI, Le Roith D: Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 2001;15: Dominici FP, Cifone D, Bartke A, Turyn D: Loss of sensitivity to insulin at early events of the insulin signaling pathway in the liver of growth hormone-transgenic mice. J Endocrinol 1999;161: Bereket A, Lang CH, Blethen SL, Gelato MC, Fan J, Frost RA, Wilson TA: Effect of insulin on the insulin-like growth factor system in children with new-onset insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1995; 80: Pao CI, Farmer PK, Begovic S, Goldstein S, Wu GJ, Phillips LS: Expression of hepatic insulin-like growth factor-i and insulin-like growth factor-binding protein-1 genes is transcriptionally regulated in streptozotocin-diabetic rats. Mol Endocrinol 1992;6: Shishko PI, Dreval AV, Abugova IA, Zajarny IU, Goncharov VC: Insulin-like growth factors and binding proteins in patients with recentonset type 1 (insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion. Diabetes Res Clin Pract 1994;25: Woods KA, Camacho-Hubner C, Bergman RN, Barter D, Clark AJ, Savage MO: Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion. J Clin Endocrinol Metab 2000;85: IGF-I in Glucose Homeostasis Horm Res 2004;62(suppl 1):
6 11 Kuzuya H, Matsuura N, Sakamoto M, Makino H, Sakamoto Y, Kadowaki T, Suzuki Y, Kobayashi M, Akazawa Y, Nomura M: Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 1993;42: Yakar S, Liu JL, Fernandez AM, Wu Y, Schally AV, Frystyk J, Chernausek SD, Mejia W, Le Roith D: Liver-specific IGF-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001;50: Haluzik M, Yakar S, Gavrilova O, Setser J, Boisclair Y, LeRoith D: Insulin resistance in the liver-specific IGF-1 gene-deleted mouse is abrogated by deletion of the acid-labile subunit of the IGF-binding protein-3 complex: relative roles of growth hormone and IGF-1 in insulin resistance. Diabetes 2003;52: Crossey PA, Jones JS, Miell JP: Dysregulation of the insulin/igf binding protein-1 axis in transgenic mice is associated with hyperinsulinemia and glucose intolerance. Diabetes 2000; 49: Moses AC, Young SC, Morrow LA, O Brien M, Clemmons DR: Recombinant human insulinlike growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996;45: RH IGF-I in NIDDM Study Group: Evidence from a dose ranging study that recombinant insulin-like growth factor-i (RhIGF-I) effectively and safely improves glycemic control in non-insulin dependent diabetes mellitus. Diabetes 1996;45(suppl 2):27A. 17 Vaessen N, Janssen JA, Heutink P, Hofman A, Lamberts SW, Oostra BA, Pols HA, van Duijn CM: Association between genetic variation in the gene for insulin-like growth factor-i and low birthweight. Lancet 2002;359: Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A, Lamberts SW, Oostra BA, Pols HA, van Duijn CM: A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001;50: Horm Res 2004;62(suppl 1):77 82 Clemmons
Endocrine Responses to Resistance Exercise
chapter 3 Endocrine Responses to Resistance Exercise Chapter Objectives Understand basic concepts of endocrinology. Explain the physiological roles of anabolic hormones. Describe hormonal responses to
More informationNew Zealand Society of Animal Production online archive
New Zealand Society of Animal Production online archive This paper is from the New Zealand Society for Animal Production online archive. NZSAP holds a regular An invitation is extended to all those involved
More informationDiabetes mellitus. Lecture Outline
Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized
More informationINSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME
1 University of Papua New Guinea School of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PBL SEMINAR INSULIN RESISTANCE, POLYCYSTIC OVARIAN
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More informationYour Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007
Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 The cardiometabolic risk syndrome is increasingly recognized
More informationALPHA (TNFa) IN OBESITY
THE ROLE OF TUMOUR NECROSIS FACTOR ALPHA (TNFa) IN OBESITY Alison Mary Morris, B.Sc (Hons) A thesis submitted to Adelaide University for the degree of Doctor of Philosophy Department of Physiology Adelaide
More informationPhysiology, Aberdeen AB24 2TZ *Corresponding authors: m.delibegovic@abdn.ac.uk, n.mody@abdn.ac.uk
In vivo differential effects of fasting, re-feeding, insulin and insulin stimulation time course on insulin signaling pathway components in peripheral insulin-sensitive tissues Abdelali Agouni 1, Carl
More informationSDS gel electrophoresis was performed using a 4% by 20% gradient gel 8. Quantification of Western blots was performed using Image J Processing and
Supplemental Material: Western blot: SDS gel electrophoresis was performed using a 4% by 20% gradient gel 8. Quantification of Western blots was performed using Image J Processing and Analysis (NIH). Quantitative
More informationEndocrine System: Practice Questions #1
Endocrine System: Practice Questions #1 1. Removing part of gland D would most likely result in A. a decrease in the secretions of other glands B. a decrease in the blood calcium level C. an increase in
More informationDescribe how these hormones exert control quickly by changes in phosphorylation state of enzyme, and more slowly by changes of gene expression
Section VIII. Section VIII. Tissue metabolism Many tissues carry out specialized functions: Ch. 43 look at different hormones affect metabolism of fuels, especially counter-insulin Ch. 44 Proteins and
More informationOverview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health
Overview of Diabetes Management By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Objectives: Describe the pathophysiology of diabetes. From a multiorgan systems viewpoint. Identify the types of diabetes.
More informationActions of Hormones on Target Cells Page 1. Actions of Hormones on Target Cells Page 2. Goals/ What You Need to Know Goals What You Need to Know
Actions of Hormones on Target Cells Graphics are used with permission of: Pearson Education Inc., publishing as Benjamin Cummings (http://www.aw-bc.com) Page 1. Actions of Hormones on Target Cells Hormones
More informationRole of Body Weight Reduction in Obesity-Associated Co-Morbidities
Obesity Role of Body Weight Reduction in JMAJ 48(1): 47 1, 2 Hideaki BUJO Professor, Department of Genome Research and Clinical Application (M6) Graduate School of Medicine, Chiba University Abstract:
More informationIntroduction. Pathogenesis of type 2 diabetes
Introduction Type 2 diabetes mellitus (t2dm) is the most prevalent form of diabetes worldwide. It is characterised by high fasting and high postprandial blood glucose concentrations (hyperglycemia). Chronic
More informationGLUCOSE HOMEOSTASIS-II: An Overview
GLUCOSE HOMEOSTASIS-II: An Overview University of Papua New Guinea School of Medicine & Health Sciences, Division of Basic Medical Sciences Discipline of Biochemistry & Molecular Biology, M Med Part I
More informationTHE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES. Key Points
December 2008 (Vol. 1, Issue 3, pages 36-40) THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES By Sophie Lotersztajn, PhD, Ariane Mallat, MD, PhD Inserm U841, Hôpital Henri Mondor,
More informationInsulin s Effects on Testosterone, Growth Hormone and IGF I Following Resistance Training
Insulin s Effects on Testosterone, Growth Hormone and IGF I Following Resistance Training By: Jason Dudley Summary Nutrition supplements with a combination of carbohydrate and protein (with a ratio of
More informationDiabetes and Drug Development
Diabetes and Drug Development Metabolic Disfunction Leads to Multiple Diseases Hypertension ( blood pressure) Metabolic Syndrome (Syndrome X) LDL HDL Lipoproteins Triglycerides FFA Hyperinsulinemia Insulin
More information1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME
1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME Izet Aganović, Tina Dušek Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia 1 Introduction The metabolic syndrome
More informationPractical Applications of Insulin Pump Therapy in Type 2 Diabetes
Practical Applications of Insulin Pump Therapy in Type 2 Diabetes Wendy Lane, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then click the activity title. Summary
More informationSEMINARS IN MEDICINE OF THE BETH ISRAEL DEACONESS MEDICAL CENTER
SEMINARS IN MEDICINE OF THE BETH ISRAEL DEACONESS MEDICAL CENTER Seminars in Medicine of the Beth Israel Deaconess Medical Center J EFFREY S. FLIER, M.D., Editor L ISA H. UNDERHILL, Assistant Editor INSULIN-LIKE
More informationDiabetes and Insulin Signaling
Diabetes and Insulin Signaling NATIONAL CENTER FOR CASE STUDY TEACHING IN SCIENCE by Kristy J. Wilson School of Mathematics and Sciences Marian University, Indianapolis, IN Part I Research Orientation
More informationRegulation of Metabolism. By Dr. Carmen Rexach Physiology Mt San Antonio College
Regulation of Metabolism By Dr. Carmen Rexach Physiology Mt San Antonio College Energy Constant need in living cells Measured in kcal carbohydrates and proteins = 4kcal/g Fats = 9kcal/g Most diets are
More informationVitamin D und seine Bedeutung im Immunsystem und bei der Infektabwehr
Vitamin D und seine Bedeutung im Immunsystem und bei der Infektabwehr Stefan Pilz Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Austria Department
More informationDIABETES AND INSULIN RESISTANCE DIABETES PREVALANCE
DIABETES AND INSULIN RESISTANCE KARI KOHRS RD LDN CDE UICMC NUTRITION & WELLNESS CENTER DIABETES PREVALANCE Third leading cause of death-- United States 18 million diagnosed Growing at the rate of 3 new
More informationThe Background for the Diabetes Detection Model
The Background for the Diabetes Detection Model James K. Peterson Department of Biological Sciences and Department of Mathematical Sciences Clemson University November 23, 2014 Outline The Background for
More informationEFFIMET 1000 XR Metformin Hydrochloride extended release tablet
BRAND NAME: Effimet XR. THERAPEUTIC CATEGORY: Anti-Diabetic PHARMACOLOGIC CLASS: Biguanides EFFIMET 1000 XR Metformin Hydrochloride extended release tablet COMPOSITION AND PRESENTATION Composition Each
More informationThe diagram below summarizes the effects of the compounds that cells use to regulate their own metabolism.
Regulation of carbohydrate metabolism Intracellular metabolic regulators Each of the control point steps in the carbohydrate metabolic pathways in effect regulates itself by responding to molecules that
More informationSupplemental Data. Article. Insulin Action in AgRP-Expressing Neurons. Is Required for Suppression. of Hepatic Glucose Production
Cell Metabolism, Volume 5 Supplemental Data Article Insulin Action in AgRP-Expressing Neurons Is Required for Suppression of Hepatic Glucose Production A. Christine Könner, Ruth Janoschek, Leona Plum,
More informationEndocrine issues in FA SUSAN R. ROSE CINCINNATI CHILDREN S HOSPITAL MEDICAL CENTER
Endocrine issues in FA SUSAN R. ROSE CINCINNATI CHILDREN S HOSPITAL MEDICAL CENTER 80% of children and adults with FA have an endocrine abnormality Endocrine cells make a hormone (message) Carried in bloodstream
More informationglucose and fatty acids to raise your blood sugar levels.
Endocrine & Cell Communication Part IV: Maintaining Balance (Homeostasis) TEACHER NOTES needs coding 1 Endocrine & Cell Communication Part IV: Maintaining Balance (Homeostasis) 2 AP Biology Curriculum
More informationHomeostatic Model Assessment (HOMA)
Homeostatic Model Assessment (HOMA) Historically, insulin resistance (IR) was measured with an invasive test called a euglycemic clamp test. Basically it s a test to measure how much insulin a person needs
More information7 Answers to end-of-chapter questions
7 Answers to end-of-chapter questions Multiple choice questions 1 B 2 B 3 A 4 B 5 A 6 D 7 C 8 C 9 B 10 B Structured questions 11 a i Maintenance of a constant internal environment within set limits i Concentration
More informationETIOLOGIC CLASSIFICATION. Type I diabetes Type II diabetes
DIABETES MELLITUS DEFINITION It is a common, chronic, metabolic syndrome characterized by hyperglycemia as a cardinal biochemical feature. Resulting from absolute lack of insulin. Abnormal metabolism of
More informationWHY THE IMPLANTABLE INSULIN PUMP WORKS SO WELL
WHY THE IMPLANTABLE INSULIN PUMP WORKS SO WELL H ave you ever wondered why it is so very difficult to manage your diabetes? There is no lack of motivation - we know how important good control is, and we
More informationDiabetes and Obesity. The diabesity epidemic
Diabetes and Obesity Frank B. Diamond, Jr. M.D. Professor of Pediatrics University of South Florida College of Medicine The diabesity epidemic Prevalence of diabetes worldwide was over 135 million people
More informationAbdulaziz Al-Subaie. Anfal Al-Shalwi
Abdulaziz Al-Subaie Anfal Al-Shalwi Introduction what is diabetes mellitus? A chronic metabolic disorder characterized by high blood glucose level caused by insulin deficiency and sometimes accompanied
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationTuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University
Tuberculosis And Diabetes Dr. hanan abuelrus Prof.of internal medicine Assiut University TUBERCULOSIS FACTS More than 9 million people fall sick with tuberculosis (TB) every year. Over 1.5 million die
More informationEffects of macronutrients on insulin resistance and insulin requirements
Effects of macronutrients on insulin resistance and insulin requirements Dr Duane Mellor RD Assistant Professor in Dietetics, The University of Nottingham, UK Outline of Discussion Issues of determining
More informationWhy is HDL Cholesterol Low in People with Insulin Resistance and Type 2 Diabetes Mellitus?
Why is HDL Cholesterol Low in People with Insulin Resistance and Type 2 Diabetes Mellitus? Henry Ginsberg, MD Columbia University College of Physicians and Surgeons Henry Ginsberg: Disclosures Research
More informationTHE EFFECT OF SODIUM CHLORIDE ON THE GLUCOSE TOLERANCE OF THE DIABETIC RAT*
THE EFFECT OF SODIUM CHLORIDE ON THE GLUCOSE TOLERANCE OF THE DIABETIC RAT* BY JAMES M. ORTEN AND HENRY B. DEVLINt (From the Deparkment of Physiological Chemistry, Wayne University College of Medicine,
More informationNursing 113. Pharmacology Principles
Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics
More informationAge Management Panel Male Fasting Panel
801 SW 16th St Suite 126 Renton WA 98057 Phone: 425.271.8689 Fax: 425.271.8689 CLIA # 50D0630590 Age Management Panel Male Fasting Panel Doctor ID 1001 Age 55 Date Collected 01/01/07 Patient Name DOE,
More informationDR. Trinh Thi Kim Hue
TYPE 2 DIABETES IN THE CHILD AND ADOLESCENT DR. Trinh Thi Kim Hue CONTENTS Definition Diagnosis Treatment Comorbidities and Complications Comorbidities and Complications Screening for T2D References DEFINITION
More informationType 2 Diabetes Mellitus and Insulin resistance syndrome in Children
Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children Anil R Kumar MD Pediatric Endocrinology MCV/VCU, Richmond VA Introduction Type 2 diabetes mellitus (T2 DM) has increased in children
More informationDRUGS FOR GLUCOSE MANAGEMENT AND DIABETES
Page 1 DRUGS FOR GLUCOSE MANAGEMENT AND DIABETES Drugs to know are: Actrapid HM Humulin R, L, U Penmix SUNALI MEHTA The three principal hormones produced by the pancreas are: Insulin: nutrient metabolism:
More informationInsulin like Growth Factors Axis and Growth Disorders
67 Symposium on Growth and Its Disorders-II Insulin like Growth Factors Axis and Growth Disorders Anurag Bajpai 1 and P.S.N. Menon 1 Department of Endocrinology and Diabetes, Center for Hormone Research,
More informationPublished Quarterly Mangalore, South India ISSN 0972-5997 Volume 4, Issue 1; January-March 2005
Published Quarterly Mangalore, South India ISSN 0972-5997 Volume 4, Issue 1; January-March 2005 Original Article Genetic Association Between Insulin Resistance And Total Cholesterol In Type 2 Diabetes
More informationINSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
More informationGrowth Hormone Therapy
Growth Hormone Therapy Policy Number: Original Effective Date: MM.04.011 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 10/28/2011 Section: Prescription Drugs Place(s) of Service:
More informationNew Insights and New Therapies for Insulin Resistance
New Insights and New Therapies for Insulin Resistance by: Johan H Koeslag Medical Physiology University of Stellenbosch PO Box 19063 Tygerberg, 7505. South Africa and: Peter T Saunders Department of Mathematics
More informationRegenerative Medicine : A Promising Approach In Overcoming Diabetes As An Increasing Economic Health Burden
Journal of Emerging Economies and Islamic Research www.jeeir.com Regenerative Medicine : A Promising Approach In Overcoming Diabetes As An Increasing Economic Health Burden Nafeeza Mohd Ismail a, Renu
More informationCME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
More informationResponse to Stress Graphics are used with permission of: Pearson Education Inc., publishing as Benjamin Cummings (http://www.aw-bc.
Response to Stress Graphics are used with permission of: Pearson Education Inc., publishing as Benjamin Cummings (http://www.aw-bc.com) Page 1. Introduction When there is an overwhelming threat to the
More informationThe Need for a PARP in vivo Pharmacodynamic Assay
The Need for a PARP in vivo Pharmacodynamic Assay Jay George, Ph.D., Chief Scientific Officer, Trevigen, Inc., Gaithersburg, MD For further infomation, please contact: William Booth, Ph.D. Tel: +44 (0)1235
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval
More informationPRESS RELEASE. Glycemic Research Institute Awards Burger King Kid-Friendly Product of the Year
PRESS RELEASE Glycemic Research Institute Awards Burger King Kid-Friendly Product of the Year August 2008 BURGER KING JOINS THE WAR AGAINST CHILDHOOD OBESITY Despite awareness of the ever-rising obesity
More informationSubcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes
Subcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes Mario R. Ehlers, 1,2 Roderick E. Harley, 1 Annette L. Mathisen, 1 Roberta Schneider,
More informationBasal Insulin Analogues Where are We Now?
232 Medicine Update 41 Basal Insulin Analogues Where are We Now? S CHANDRU, V MOHAN Insulin is a polypeptide secreted by the beta cells of pancreas and consists of 51 amino acids (AA). It has two polypeptide
More informationGive a NOD to diabetes:
Give a NOD to diabetes: NOD proteins ti link immunity it and metabolism tbli Jonathan Schertzer McMaster University McMaster University Faculty of Health Sciences Department of Biochemistry and Biomedical
More informationPlasma glucose and insulin responses to mixed meals: Impaired fasting glucose re-visited
421036DVR8410.1177/1479164111421036Bhat et al.diabetes and Vascular Disease Research Orginal Article Plasma glucose and insulin responses to mixed meals: Impaired fasting glucose re-visited Diabetes &
More informationCardiovascular Disease Risk Factors Part XII Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005
Cardiovascular Disease Risk Factors Part XII By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005 As we approach the end of our extended series on cardiovascular disease risk factors,
More informationTeriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).
Page 1 of 10 ANALYTE NAME AND STRUCTURE TERIFLUNOMIDE Teriflunomide TRADE NAME Aubagio CATEGORY Antimetabolite TEST CODE PURPOSE Therapeutic Drug Monitoring GENERAL RELEVANCY BACKGROUND sclerosis. The
More informationInternet: Domain Names owned: www.vasc-surgery.com, www.vascsurgeon.com, www.aortasurgery.com
STEPHEN JOEL MOTEW, MD, FACS Work: Salem Surgical Associates, PA 2915 Lyndhurst Ave. Winston-Salem, NC 27103 (336) 765-5221 Internet: Domain Names owned: www.vasc-surgery.com, www.vascsurgeon.com, www.aortasurgery.com
More informationClass time required: Two 40-minute class periods + homework. Part 1 may be done as pre-lab homework
Diagnosing Diabetes Teacher information Summary: Students analyze simulated blood plasma samples collected during a glucose tolerance test for diabetes. They test glucose and insulin levels to determine
More informationESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease
Diabetes, prediabetes and cardiovascular disease Classes of recommendations Levels of evidence Recommended treatment targets for patients with diabetes and CAD Definition, classification and screening
More informationThe insulin and insulin-like growth factor receptor family in neoplasia: an update
The insulin and insulin-like growth factor receptor family in neoplasia: an update Michael Pollak 1 Abstract Although several early phase clinical trials raised enthusiasm for the use of insulin-like growth
More informationObtaining insurance coverage for human growth hormone treatment for Idiopathic Short Stature In 2003, the Food and Drug Administration (FDA) approved
Obtaining insurance coverage for human growth hormone treatment for Idiopathic Short Stature In 2003, the Food and Drug Administration (FDA) approved the use of growth hormone (GH) for the long-term treatment
More informationSweet-taste receptors, glucose absorption and insulin release: Are LCS nutritionally active?
Sweet-taste receptors, glucose absorption and insulin release: Are LCS nutritionally active? Samuel V. Molinary, Ph.D. Consultant, Scientific & Regulatory Affairs ILSI/NA April 6, 2011 Washington, DC Why
More informationGloP1r - A New Frontier in Exercise and Nutrition
Central Florida Research Update Ayala, Julio, PhD, Sanford-Burnham Medical Research Institute, Orlando, Florida Anorectic Mechanisms of Glp1r Agonists Obesity Jan 1, 2014 Dec 31, 2018 Integrated Physiology,
More informationOrdering and interpreting thyroid tests in children. Paul Kaplowitz, MD, PhD Children s National Medical Center, Washington, DC
Ordering and interpreting thyroid tests in children Paul Kaplowitz, MD, PhD Children s National Medical Center, Washington, DC Objectives To review indications for thyroid testing To discuss which tests
More informationMind the Gap: Navigating the Underground World of DKA. Objectives. Back That Train Up! 9/26/2014
Mind the Gap: Navigating the Underground World of DKA Christina Canfield, MSN, RN, ACNS-BC, CCRN Clinical Nurse Specialist Cleveland Clinic Respiratory Institute Objectives Upon completion of this activity
More informationPhil. J. Internal Medicine, 47: 25-30, Jan.-Feb., 2009
Original Articles Pancreatic Insulin Response among Filipino 25 Phil. J. Internal Medicine, 47: 25-3, Jan.-Feb., 29 COMPARISON OF PANCREATIC INSULIN RESPONSE TO GLYCEMIA AMONG FILIPINO SUBJECTS OF VARIOUS
More informationMuscular dystrophy clinical manifestations: progressive proximal extremity weakness respiratory muscle weakness cardiomyopathy
Muscular dystrophy clinical manifestations: progressive proximal extremity weakness respiratory muscle weakness cardiomyopathy Muscular dystrophy pathology: muscle fiber degeneration and regeneration Muscular
More informationGLUCOHelp. A fast-acting, clinically proven way to control blood glucose levels. Banaba Leaf Extract, Standardized to 18% Corosolic Acid
A fast-acting, clinically proven way to control blood glucose levels GLUCOHelp Banaba Leaf Extract, Standardized to 18% Corosolic Acid www.optipure.com 9 GLUCOHelp A fast-acting, clinically proven way
More informationGetting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research?
Getting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research? Jody Dushay, MD MMSc Beth Israel Deaconess Medical Center Boston, MA Session 445 No disclosures Disclosure Jody Dushay,
More informationCONTRACTING ORGANIZATION: University of Alabama at Birmingham Birmingham, AL 35294
AD Award Number: W81XWH-08-1-0030 TITLE: Regulation of Prostate Cancer Bone Metastasis by DKK1 PRINCIPAL INVESTIGATOR: Gregory A. Clines, M.D., Ph.D. CONTRACTING ORGANIZATION: University of Alabama at
More informationStamcelleforskning- helbreder diabetes? Diabetes, beta cells and stem cell based therapy
1 Stamcelleforskning- helbreder diabetes? Diabetes, beta cells and stem cell based therapy Ole D. Madsen Senior Principal Scientist Diabetes Biology Novo Nordisk A/S Honorary Professor in Diabetes Stem
More informationDiagnosis, classification and prevention of diabetes
Diagnosis, classification and prevention of diabetes Section 1 1 of 4 Curriculum Module II 1 Diagnosis, classification and presentation of diabetes Slide 2 of 48 Polyurea Definition of diabetes Slide 3
More informationChapter 8. Summary and Perspectives
Chapter 8 Summary and Perspectives 131 Chapter 8 Summary Overexpression of the multidrug resistance protein MRP1 confer multidrug resistance (MDR) to cancer cells. The contents of this thesis describe
More informationEndocrine Glands and the General Principles of Hormone Action
Endocrine Glands and the General Principles of Hormone Action Cai Li, Ph.D. Assistant professor Touchstone Center for Diabetes Research Departments of Physiology and Internal Medicine The University of
More information2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line
i 1 INTRODUCTION 1.1 Human Hepatitis B virus (HBV) 1 1.1.1 Pathogenesis of Hepatitis B 1 1.1.2 Genome organization of HBV 3 1.1.3 Structure of HBV virion 5 1.1.4 HBV life cycle 5 1.1.5 Experimental models
More information25-hydroxyvitamin D: from bone and mineral to general health marker
DIABETES 25 OH Vitamin D TOTAL Assay 25-hydroxyvitamin D: from bone and mineral to general health marker FOR OUTSIDE THE US AND CANADA ONLY Vitamin D Receptors Brain Heart Breast Colon Pancreas Prostate
More informationOverview of Metabolism. Peds 231 April 9, 2009 Julie Theriot
Overview of Metabolism Peds 231 April 9, 2009 Julie Theriot Outline What is metabolism and why should you care about it? Summary of human carbohydrate metabolism and connections to diabetes Metabolism
More informationtrends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223-
Review Article Pharmacological trends in the treatment of Diabetes type 2 - New classes of antidiabetic Silvia Mihailova 1*, Antoaneta Tsvetkova 1, Anna Todorova 2 1 Assistant Pharmacist, Education and
More informationInsulin Infusion Pumps
Medical Coverage Policy Insulin Infusion Pumps EFFECTIVE DATE: 09/01/2004 POLICY LAST UPDATED: 08/06/2013 OVERVIEW The policy addresses insulin infusion pumps that are worn externally and those that are
More informationDiabetes and Obesity in Children. Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO
Diabetes and Obesity in Children Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO Diabetes and Obesity in Children What is Diabetes? How are Diabetes and Obesity
More informationInsulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types
Insulin Therapy In Type 2 DM Michael Fischer, M.D., M.S. Sources of support NaRCAD is supported by a grant from the Agency for Healthcare Research and Quality My current research projects are funded by
More informationAltitude. Thermoregulation & Extreme Environments. The Stress of Altitude. Reduced PO 2. O 2 Transport Cascade. Oxygen loading at altitude:
Altitude Thermoregulation & Extreme Environments Reduced PO 2 The Stress of Altitude O 2 Transport Cascade Progressive change in environments oxygen pressure & various body areas Oxygen loading at altitude:
More informationCauses, incidence, and risk factors
Causes, incidence, and risk factors Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both. To understand diabetes,
More information6.4 Diabetes. 6 Priority diseases and reasons for inclusion. Background. Developments since 2004. See Background Paper 6.4 (BP6_4DM.
6 Priority diseases and reasons for inclusion 6.4 Diabetes See Background Paper 6.4 (BP6_4DM.pdf) Background Diabetes and diabetes-related illnesses place an enormous burden on the health care systems
More informationVersion 1 2015. Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen
Version 1 2015 Module guide International Master Program Cardiovascular Science University of Göttingen Part 1 Theoretical modules Synopsis The Master program Cardiovascular Science contains four theoretical
More informationA STUDY OF MAGNESIUM SUPPLEMENTATION ON GLYCEMIC CONTROL IN PATIENTS OF TYPE-2 DIABETES MELLITUS
RESEARCH ARTICLE A STUDY OF MAGNESIUM SUPPLEMENTATION ON GLYCEMIC CONTROL IN PATIENTS OF TYPE-2 DIABETES MELLITUS Yogendra Raj Singh 1, Shilpi Verma 2, Dushyant Agrawal 3,*, Brijendra Singh 4, Ashutosh
More informationBlood Testing Protocols. Disclaimer
Blood Testing Protocols / Page 2 Blood Testing Protocols Here are the specific test protocols recommend by Dr. J.E. Williams. You may request these from your doctor or visit www.readyourbloodtest.com to
More informationMechanism of hormone action
Mechanism of hormone action ผศ.ดร.พญ.ส ว ฒณ ค ปต ว ฒ ภาคว ชาสร รว ทยา คณะแพทยศาสตร ศ ร ราชพยาบาล Aims What is hormone receptor Type of hormone receptors - cell surface receptor - intracellular receptor
More informationIs Insulin Effecting Your Weight Loss and Your Health?
Is Insulin Effecting Your Weight Loss and Your Health? Teressa Alexander, M.D., FACOG Women s Healthcare Associates www.rushcopley.com/whca 630-978-6886 Obesity is Epidemic in the US 2/3rds of U.S. adults
More informationDietfree-Good News for Diabetics
Dietfree-Good News for Diabetics What is Dietfree? Dietfree is concentrated herbs developed Superdragon TCM UK Ltd and Chinese Medical Academy UK. It is made from a range of pure natural concentrated Chinese
More information